Drugs / Human Umbilical Cord Derived MSC
Human Umbilical Cord Derived MSC
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01754454 | Dec 2012 → Dec 2016 | acute graft versus host disease | Affiliated Hospital to Academy of Military Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT01547689 | Mar 2012 → Dec 2016 | Alzheimer disease | Affiliated Hospital to Academy of Military Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT01741857 | Jan 2012 → Dec 2013 | systemic lupus erythematosus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Umbilical Cord Derived MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01547689 ↗ |
| Known as | Allogenic MSC derived from umbilical cord | “Allogenic MSC derived from umbilical cord” NCT01741857 ↗ |
| Known as | Other Name: UC-MSC | “Other Name: UC-MSC” NCT01547689 ↗ |
| Known as | UC-MSCs | “Allogeneic umbilical cord-derived MSCs (UC-MSCs) on inhibition of T cell proliferation were determined.” PMID 24756936 ↗ Aug 2014 |
| Modality | Cell therapy | “Mesenchymal stem cells (MSCs) are multipotent cells that are being clinically explored as a new therapeutic” NCT01547689 ↗ |
| Route | Intravenous | “intravenous injection” NCT01547689 ↗ |